SCCA physicians to present their research at Genitourinary Cancers Symposium
Seattle Cancer Care Alliance (SCCA), UW Medicine, and Fred Hutch physicians and researchers who are leaders in treating genitourinary cancers will attend and present their research at the Genitourinary Cancers Symposium taking place Feb. 14-16 in San Francisco. The symposium will feature an array of multidisciplinary sessions covering prostate, renal, urothelial, penile, testicular, and adrenal cancers. World-renowned faculty, including our own, will discuss the latest clinically relevant topics with a focus on multimodality therapy and value in cancer care.
SCCA physicians are experts in genitourinary cancer treatments, treating patients in state-of-the-art multidisciplinary clinics like the Bladder Cancer Multispecialty Clinic and the Kidney Cancer Multispecialty Clinic that bring together our experienced, nationally known urologic oncologists, radiation oncologists and medical oncologists. Our team is dedicated to giving genitourinary cancer patients access to the most innovative therapies through more than 60 clinical trials available for patients with bladder cancer, kidney cancer, prostate cancer, and testicular cancer.
Our genitourinary experts will be presenting their research in both oral presentations and poster sessions throughout the three-day event. Highlights include multiple poster sessions from Dr. Celestia Higano, who is also program director for the satellite symposium on PARP inhibitors and genetic testing in prostate cancer. The title of the symposium is: “A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer.” Dr. Evan Yu will present about a clinical trial combining a PARP inhibitor and a PD-1 antibody that is showing promising results in men with metastatic castration-resistant prostate cancer.
Abstract 145: Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
First Author: Evan Yu, MD
Friday, Feb. 15:
12:15 PM-1:45 PM; 5:15 PM-6:15 PM
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Poster Board: F6
Brian Winters, MD
Abstract 371: Distinct genomic hallmarks exist between metastatic upper and lower tract urothelial carcinoma. Winters and colleagues utilized their unique rapid autopsy program to define and compare the mutational landscape of primary and metastatic UTUC and LTUC. In these patients, metastatic UTUC appears to have a lower overall mutational burden but greater genomic variability compared to LTUC. These data suggest that metastatic UTUC displays a greater spectrum of mutational divergence from LTUC which may partially explain differences in clinical behavior. Further, the results reveal similarities across metastatic sites within these patients with implications for therapeutic vulnerabilities.
Poster Board: J12
Yaw Nyame, MD, MBA
Abstract 441: Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?
Saturday, Feb. 16:
7:55 AM-9:30 AM
Informing the Decision Using Data Science - Sarah Psutka, MD, MS, discusses body composition changes in men with advanced germ cell cancers of the testis receiving platinum-based chemotherapy
Additional Poster Sessions:
Arora K, Kato, C, Batra KK, Mullane M, Lad T, Master VA, Psutka SP. Increasing Adipose Burden in Young Men with Testicular Cancer following Front-Line Cytotoxic Chemotherapy. Abstract 525.
Yaw Nyame, MD, MBA, Board J12 , Abstract 441: Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?
Tia Higano, MD Abstract 253: Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Tia Higano, MD Abstract TPS342: TALAPRO-1: An open-label, response rate phase 2 study of talazoparib in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on > 1 novel hormonal therapy (NHT)